نتائج البحث

Two risk factors for hypozincemia in diabetic β-thalassemia patients: Hepatitis C and deferasirox.

• Authors : Darvishi-Khezri H; Thalassemia Research Center (TRC), Hemoglobinopathy Institute, Mazandaran University of Medical Sciences, Sari, Iran.; Karami H

Subjects: beta-Thalassemia*/beta-Thalassemia*/beta-Thalassemia*/complications ; beta-Thalassemia*/beta-Thalassemia*/beta-Thalassemia*/drug therapy ; Iron Overload*/Iron Overload*/Iron Overload*/complications

• Source: PloS one [PLoS One] 2024 Jan 12; Vol. 19 (1), pp. e0284267. Date of Electronic Publication: 2024 Jan 12 (Print Publication: 2024).Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet

تفاصيل العنوان

Safety and efficacy of deferasirox in patients with transfusion-dependent thalassemia: A 4-year single-center experience.

• Authors : Zengin Ersoy G; Pediatric Hematology Oncology, Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Turkey.; Ayçiçek A

Subjects: Deferasirox/Deferasirox/Deferasirox/*administration & dosage ; Deferasirox/Deferasirox/Deferasirox/*pharmacokinetics ; Thalassemia/Thalassemia/Thalassemia/*blood

• Source: Pediatric hematology and oncology [Pediatr Hematol Oncol] 2021 Sep; Vol. 38 (6), pp. 555-563. Date of Electronic Publication: 2021 Mar 22.Publisher: Informa Healthcare Country of Publication: England NLM ID: 8700164 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

Comparison of Deferasirox and Desferoxamine in Patients of β-Thalassemia Major With Iron Overload

• Source: Comparison of Deferasirox and Desferoxamine in Patients of β-Thalassemia Major With Iron Overload

تفاصيل العنوان

Assessing the auditory effects of oral chelation therapy drug Deferasirox in individuals with β‐thalassemia major

• Authors : Balwinder S. Tiwana; Ankita Aggarwal; Sanjeev Bhagat

Subjects: auditory; deferasirox; distortion product otoacoustic emissions

• Source: World Journal of Otorhinolaryngology-Head and Neck Surgery, Vol 10, Iss 4, Pp 309-314 (2024)

تفاصيل العنوان

Pharmacological and clinical evaluation of deferasirox formulations for treatment tailoring.

• Authors : Piolatto A; Department of Clinical and Biological Sciences, University of Torino, Torino, Italy. .; Berchialla P

Subjects: Anemia/Anemia/Anemia/*drug therapy ; Deferasirox/Deferasirox/Deferasirox/*administration & dosage ; Iron Overload/Iron Overload/Iron Overload/*drug therapy

• Source: Scientific reports [Sci Rep] 2021 Jun 15; Vol. 11 (1), pp. 12581. Date of Electronic Publication: 2021 Jun 15.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

Pilot Study for Patients With Poor Response to Deferasirox

• Authors : Novartis; Ellis Neufeld, Professor of Pediatrics

• Source: Pilot Pharmacokinetic Study In Patients With Inadequate Response To Deferasirox (Exjade)Chirnomas D, Smith AL, Braunstein J, Finkelstein Y, Pereira L, Bergmann AK,

تفاصيل العنوان

The impact of chelation compliance in health outcome and health related quality of life in thalassaemia patients: a systematic review.

• Authors : Lee WJ; Centre of Quality Management of Medicines, Faculty of Pharmacy, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.; Mohd Tahir NA

Subjects: Iron Chelating Agents*/Iron Chelating Agents*/Iron Chelating Agents*/therapeutic use ; Thalassemia*/Thalassemia*/Thalassemia*/drug therapy; Humans

• Source: Health and quality of life outcomes [Health Qual Life Outcomes] 2024 Feb 02; Vol. 22 (1), pp. 14. Date of Electronic Publication: 2024 Feb 02.Publisher: BioMed Central Country of Publication: England NLM ID: 101153626 Publication Model: Electronic Cited Medium: Internet ISSN: 1477-7525

تفاصيل العنوان

Deferasirox in children with transfusion-dependent thalassemia or sickle cell anemia: A large cohort real-life experience from Turkey (REACH-THEM).

• Authors : Antmen B; Acıbadem Hospital, Adana, Turkey.; Karakaş Z

Subjects: Anemia, Sickle Cell/Anemia, Sickle Cell/Anemia, Sickle Cell/*complications ; Deferasirox/Deferasirox/Deferasirox/*therapeutic use ; Iron Chelating Agents/Iron Chelating Agents/Iron Chelating Agents/*therapeutic use

• Source: European journal of haematology [Eur J Haematol] 2019 Feb; Vol. 102 (2), pp. 123-130. Date of Electronic Publication: 2018 Dec 09.Publisher: Blackwell Country of Publication: England NLM ID: 8703985 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1600-0609

تفاصيل العنوان

Highlights on Deferasirox Use and its Renal Toxicity in Children with Beta Thalassemia Major.

• Authors : Ahmed, Hanan Abdelaziz¹ ; Salama, Khaled M.¹; Kaddah, Ahmed M.¹

Subjects: *BETA-Thalassemia; *NEPHROTOXICOLOGY; *HYPERFERRITINEMIA

• Source: Egyptian Journal of Hospital Medicine. Jan2023, Vol. 90 Issue 1, p1115-1119. 5p.

تفاصيل العنوان

Optimising management of deferasirox therapy for patients with transfusion-dependent thalassaemia and lower-risk myelodysplastic syndromes.

• Authors : Kattamis A; First Department of Pediatrics, National and Kapodistrian University of Athens, Athens, Greece.; Aydinok Y

Subjects: Deferasirox/Deferasirox/Deferasirox/*therapeutic use ; Iron Chelating Agents/Iron Chelating Agents/Iron Chelating Agents/*therapeutic use ; Iron Overload/Iron Overload/Iron Overload/*drug therapy

• Source: European journal of haematology [Eur J Haematol] 2018 Sep; Vol. 101 (3), pp. 272-282. Date of Electronic Publication: 2018 Jul 27.Publisher: Blackwell Country of Publication: England NLM ID: 8703985 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1600-0609

تفاصيل العنوان